Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
Simon Couillard(Université de Sherbrooke), Ian Pavord(University of Oxford), Maisha Jabeen(University of Oxford), Sanjay Ramakrishnan(The University of Western Australia), Annette Laugerud, J. Mark Melhorn(University of Oxford), Timothy Hinks(University of Oxford)
Cited by 169
Related Papers
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Severe eosinophilic asthma: a roadmap to consensus
|European Respiratory Journal|2017|187
Current evidence and future research needs for FeNO measurement in respiratory diseases
|Respiratory Medicine|2014|183